Literature DB >> 30953702

Medical therapy for frontal fibrosing alopecia: A review and clinical approach.

Anthony Ho1, Jerry Shapiro2.   

Abstract

BACKGROUND: Guidelines for the treatment of frontal fibrosing alopecia (FFA) are limited, and the literature on treatment modalities consists mostly of case reports and cohort studies.
OBJECTIVES: In this review, we sought to assess the response of medical therapy for FFA and propose a clinical approach to management.
METHODS: A literature search for "frontal fibrosing alopecia" on PubMed returned 270 items. In this review, only studies with treatment regimens and reported outcomes were considered. The majority of studies found were case reports and retrospective cohort studies. Response to therapy was assessed by reported ability to slow or arrest hair loss.
RESULTS: Intralesional steroids and 5α-reductase inhibitors were the most commonly used therapies with the most positive treatment responses (88%, 181/204 for intralesional steroids and 88%, 158/180 for 5α-reductase inhibitors). Oral prednisone was seldom used and only temporarily delayed rapid hair loss. Other therapies evaluated included topical steroids, antibiotics, pioglitazone, systemic retinoids, and hair transplantation. LIMITATIONS: Lack of placebo control studies and uniform outcome measures.
CONCLUSION: The natural course of FFA is variable. Recession of the frontal hairline might stabilize regardless of treatment. However, early intervention is encouraged in active disease because hair loss is presumed permanent and treatment could modify the disease course.
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  frontal fibrosing alopecia; hair loss; inflammatory hair disorder; medical management; primary lymphocytic cicatricial alopecia

Year:  2019        PMID: 30953702     DOI: 10.1016/j.jaad.2019.03.079

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  [Translated article] Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19.

Authors:  D Morgado-Carrasco; J Ibaceta-Ayala; J Piquero-Casals
Journal:  Actas Dermosifiliogr       Date:  2022-02

Review 2.  Beneficial Extracardiac Effects of Cardiovascular Medications.

Authors:  Asra K Butt; Jay Patel; Hamid Shirwany; Qasim Mirza; Jonathan Hoover; Rami N Khouzam
Journal:  Curr Cardiol Rev       Date:  2022

Review 3.  Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features.

Authors:  Carolina Oliveira Costa Fechine; Neusa Yuriko Sakai Valente; Ricardo Romiti
Journal:  An Bras Dermatol       Date:  2022-04-02       Impact factor: 2.113

4.  Hair Loss in Lichen Planopilaris and Frontal Fibrosing Alopecia: Not Always Irreversible.

Authors:  Prag Batra; Kumar Sukhdeo; Jerry Shapiro
Journal:  Skin Appendage Disord       Date:  2020-01-31

5.  Comprehensive Analysis of LncRNA AC010789.1 Delays Androgenic Alopecia Progression by Targeting MicroRNA-21 and the Wnt/β-Catenin Signaling Pathway in Hair Follicle Stem Cells.

Authors:  Jiachao Xiong; Baojin Wu; Qiang Hou; Xin Huang; Lingling Jia; Yufei Li; Hua Jiang
Journal:  Front Genet       Date:  2022-02-15       Impact factor: 4.599

6.  Frontal Fibrosing Alopecia Mimicking Alopecia Syphilitica.

Authors:  Kyra L Diehl; Christof P Erickson; Antoanella Calame; Philip R Cohen
Journal:  Cureus       Date:  2022-02-04

7.  Eyebrow hair loss as a prognostic factor for frontal fibrosing alopecia.

Authors:  Reese L Imhof; Beija Villalpando; Sydney Proffer; Hafsa Cantwell; Stanislav Tolkachjov; Rochelle Torgerson
Journal:  JAAD Int       Date:  2022-08-18

8.  A Cell Membrane-Level Approach to Cicatricial Alopecia Management: Is Caveolin-1 a Viable Therapeutic Target in Frontal Fibrosing Alopecia?

Authors:  Ivan Jozic; Jérémy Chéret; Beatriz Abdo Abujamra; Mariya Miteva; Jennifer Gherardini; Ralf Paus
Journal:  Biomedicines       Date:  2021-05-19

9.  [Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19].

Authors:  D Morgado-Carrasco; J Ibaceta-Ayala; J Piquero-Casals
Journal:  Actas Dermosifiliogr       Date:  2021-08-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.